Highest-materiality recent filing
Bankruptcy Court confirmed prepackaged Chapter 11 plan on July 21, 2026; company converted to New GoHealth, LLC.
GoHealth receives Nasdaq delisting notice after Chapter 11 filing; trading suspended June 16
Nasdaq delisting based on Chapter 11 filing, public interest concerns, and residual equity holder issues.
GoHealth files for Chapter 11 bankruptcy with prepackaged plan supported by 100% of lenders
GoHealth filed Chapter 11 on June 7, 2026; 100% of lenders, >60% of Class A common holders, and >99% of GoHealth Holdings unitholders support the prepackaged plan.
No GAAP or adjusted EPS, revenue, or net income provided in the press release.
GoHealth receives Nasdaq delisting notice for failure to meet $35M market value requirement
Notice dated March 18, 2026 for non-compliance with MVLS Requirement (min $35M market value of listed securities).
GoHealth reports Q3 2025 results with intentional MA volume pullback; no financial figures disclosed
Intentionally reduced Medicare Advantage volume in response to health plan focus on renewal stability and unit economics.
GoHealth appoints Mark Weinsten and Bao Truong to board; Gelber and Modi resign
Jeremy W. Gelber and Abhiraj Modi resigned from the Board effective August 19, 2025; no disagreement with company.
Secured $115M superpriority term loan facility with $80M in new-money term loans and $35M in roll-up loans.
Extends revolving credit maturity from June 30 to September 30, 2025, and waives financial covenant testing for Q2 and Q3 2025.
Elected Brandon M. Cruz, Alan Wheatley, and Abhiraj R. Modi as Class II directors with >95% of votes cast.
GoHealth Q1 net revenue $221M (+19% YoY); Adjusted EBITDA $42.1M (+56%)
Net revenue $221.0M, up 19.1% YoY from $185.6M; net loss narrowed to $9.8M from $21.3M.
GoHealth extends CEO Kotte's contract to 2028; $1M salary, $5M equity, $3M cash retention
CEO term extended to April 1, 2028; base salary raised to $1M per year.
GoHealth Q4 net revenue up 41% to $389M; net income $58M vs prior year loss
Q4 net revenues $389.1M (+41% YoY); full-year net revenues $798.9M (+9% YoY).
GoHealth Q3 net income $15.4M vs loss $56.2M; acquires e-TeleQuote at bargain gain $77.4M
Q3 net revenues $118.3M, down $13.7M from $132.0M a year ago.
GoHealth appoints Brendan Shanahan as CFO; O'Halloran becomes CAO
Brendan Shanahan appointed CFO effective Oct 14, 2024; has 30+ years financial leadership and Medicare Advantage expertise.
GoHealth closes acquisition of e-TeleQuote; gains ~$100M in contract assets and $18M cash
Acquisition closed on Sept 30, 2024; GoHealth invested $5M for newly issued shares and became sole owner after previous owner relinquished 81.1% stake.
GoHealth to acquire e-TeleQuote Insurance, gaining full ownership by Sept 30, 2024
GoHealth subsidiary will acquire newly issued shares representing ~18.9% of e-TeleQuote, then current parent surrenders all rights, making ETQ wholly-owned.
GoHealth Q2 2024 net revenues $105.9M, down 26% YoY; net loss improves to $59.3M
Net revenues of $105.9M, a decrease of $36.9M from $142.8M in Q2 2023.
GoHealth appoints two new directors, Alan Wheatley and Abhiraj Modi; Christopher Litchford resigns
Alan Wheatley, former President of Medicare at Humana (1991-2022), appointed as Class II director effective July 9, 2024.
Joseph G. Flanagan resigned from Board effective June 25, 2024; served as Class II director and Chair of Nominating and Corporate Governance Committee.
GoHealth awards interim CFO Katherine O'Halloran $75k bonus and 25k RSUs
Former CFO Jason Schulz resigned effective June 4, 2024; Katherine O'Halloran appointed interim CFO.
Alexander Timm (17.6M for), David Fisher (17.3M for), Vijay Kotte (17.8M for) elected Class I directors.
GoHealth CFO Jason Schulz resigns; CAO Katherine O'Halloran named interim CFO
Jason Schulz resigned as CFO effective June 4, 2024, for personal reasons; no disagreement with company.
GoHealth Q1 net revenues $185.6M, up slightly; net loss narrows to $21.3M
Net revenues of $185.6M vs $183.2M in Q1 2023, a slight increase.
GoHealth reports Q4 net loss down 98.5% to $2.3M; FY 2023 Adj. EBITDA $75.1M
Q4 net revenues $276.7M vs $69.4M YoY; FY net rev $734.7M vs $631.7M.
GoHealth reports FY2023 cash from ops up 79% to $109.1M; Q4 rev $276.7M
Q4 2023 net revenue $276.7M vs $69.4M YoY; full-year $734.7M vs $631.7M.
GoHealth Q3 net loss narrows to $56.2M; submissions jump 31% YoY
Q3 2023 net revenues $132.0M vs $133.1M YoY; net loss improved to $56.2M from $74.7M.
GoHealth Q2 revenue falls 10% to $142.8M, but Adj EBITDA positive; rejects $20/share bid
Q2 net revenue $142.8M, down 10% YoY from $158.7M; net loss improved to $70.2M from $113.8M.
Chief Strategy Officer Shane Cruz's employment terminates June 30, 2023 after nearly 20 years at GoHealth.
GoHealth stockholders elect three Class III directors, ratify auditor, approve say-on-pay
Clinton P. Jones, Jeremy W. Gelber, and Karolina H. Hilu elected as Class III directors with >16.4M votes each.
GoHealth Q1 net loss narrows to $22.5M; Adj EBITDA $28.8M, guides FY23 $750-850M revenue
Net loss of $22.5M (vs. -$37.2M YoY); net revenue $183.2M (down from $270.6M).
GoHealth enters credit agreement amendment replacing LIBOR with Term SOFR
Amendment No. 10 converts existing LIBOR-based rate to Term SOFR with spread adjustment of 0.10%/0.15%/0.25%.
GoHealth Q4 net loss $150.7M, FY net loss $376.4M; guides 2023 rev $750-850M
Q4 net revenue $69.4M, net loss $150.7M, Adj EBITDA -$94.8M; FY net revenue $631.7M, net loss $376.4M, Adj EBITDA -$129.8M.
GoHealth reports positive FY2022 cash flow from operations, ahead of target
Positive cash flow from operations in FY2022, >$300M improvement vs FY2021, ahead of H1 2023 target.
GoHealth appoints Karolina Hilu as Class III director effective Jan 5, 2023
Ms. Hilu is an independent director and advisor to health tech companies, former CEO of Emsana Health.
GoHealth regains Nasdaq minimum bid price compliance
Received letter from Nasdaq on December 5, 2022 confirming compliance with Listing Rule 5550(a)(2).
Nasdaq granted additional 180 days until May 22, 2023 to meet minimum bid price of $1.00.
GoHealth announces 1-for-15 reverse stock split effective November 17, 2022
Stockholders approved reverse split ratio range of 1:5 to 1:15 at October 24 special meeting.
GoHealth Q3 net revenue down 37% to $133.1M; net loss widens to $74.7M
Medicare Submitted Policies Q3: 132,831, down 34% YoY; YTD up 11% to 611,385.
GoHealth shareholders approve reverse stock split at ratio between 1-for-5 and 1-for-15
Approximately 91% of outstanding shares voted; 288,575,991 for, 5,864,651 against, 192,740 abstain.
GoHealth receives $50M strategic investment from Anthem, issues 7% convertible preferred
Issued 50,000 shares of Series A Convertible Perpetual Preferred at $1,000/share for $50M total.
GoHealth director Tawil resigns; Christopher Litchford appointed as Centerbridge designee
Tawil resigned as Centerbridge director on Sept 11, 2022; no disagreement with GoHealth.
GoHealth amends credit agreement, raises interest rates on term loans to LIBOR+7.50%
Interest on 2021 Incremental Term Loans set to ABR+6.50% or LIBOR+7.50%.
GoHealth Q2 net revenue $158.7M (-19% YoY), net loss $113.8M; cuts 23.7% of workforce
Medicare Submitted Policies of 177,911 up 9% YoY; YTD up 38%.
GoHealth COO Shane Cruz transitions to Chief Strategy Officer; COO role vacant
Shane Cruz moved from COO to Chief Strategy Officer effective July 11, 2022.
GoHealth appoints new CEO and CFO; co-founders Jones and Cruz transition roles
Vijay Kotte appointed CEO effective June 6, 2022, succeeding Clinton P. Jones who becomes Executive Chair through Dec 31, 2022.
GoHealth receives Nasdaq minimum bid price deficiency notice; appoints David Fisher to board
Received Nasdaq notice for bid price below $1.00 for 30 consecutive days; compliance period through Nov 21, 2022.
GoHealth Q1 net revenue up 33% to $270.6M, but net loss widens to $37.2M; reaffirms FY guidance
Revenue $270.6M (+33% YoY); net loss $37.2M vs $7.3M loss in prior year.
GoHealth receives NASDAQ notice for audit committee noncompliance after director resignation
NASDAQ notified GoHealth on April 29, 2022 of noncompliance with Rule 5605(c)(2) requiring at least three independent audit committee members.
GoHealth reprices employee stock options to $1.05/share to retain key contributors
Board approved repricing of outstanding options for current employees to $1.05, a premium to $0.77 close.
Immediately following such dissolution, the following individuals were appointed directors of Reorganized GoHealth: Vijay Kotte, Scott Avila, Neal Goldman and Conor Colpoys .
Immediately following such dissolution, the following individuals were appointed directors of Reorganized GoHealth: Vijay Kotte, Scott Avila, Neal Goldman and Conor Colpoys .
Immediately following such dissolution, the following individuals were appointed directors of Reorganized GoHealth: Vijay Kotte, Scott Avila, Neal Goldman and Conor Colpoys .
Immediately following such dissolution, the following individuals were appointed directors of Reorganized GoHealth: Vijay Kotte, Scott Avila, Neal Goldman and Conor Colpoys .
The Company and Michael Hargis, its Chief Operating Officer, agreed that Mr. Hargis will be leaving the Company to pursue other opportunities on June 5, 2026.
appointed Brendan Shanahan as the Company’s Chief Financial Officer, effective October 14, 2024
Ms. O’Halloran, the Company’s current Interim Chief Financial Officer, will continue her service to the Company as Chief Accounting Officer following Mr. Shanahan’s appointment as Chief Financial Officer.
On July 9, 2024, the Board of Directors (the “Board”) of GoHealth, Inc. (the “Company”) appointed Alan Wheatley as a Class II director of the Board, effective immediately.
On July 8, 2024, Christopher C. Litchford, a member of the Board, informed the Company of his intent to resign from the Board effective July 8, 2024.
On July 9, 2024, the Board appointed Abhiraj R. Modi as a Class II director of the Board.
Joseph G. Flanagan, a member of the Board of Directors (the “Board”) of GoHealth, Inc. (the “Company”), informed the Company of his intent to resign from the Board effective June 25, 2024.
Alexander Timm will replace Mr. Flanagan as lead independent director.
Max materiality 1.00 · Median 0.65 · Most common event earnings